Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160)
Hill NR., Lasserson D., Thompson B., Perera-Salazar R., Wolstenholme J., Bower P., Blakeman T., Fitzmaurice D., Little P., Feder G., Qureshi N., Taal M., Townend J., Ferro C., McManus R., Hobbs FDR.
Following publication of the original article , an error was identified between the primary outcome specified in the original protocol, the detailed SAP, and the endpoint forms and a later version of the protocol that this paper was based upon. The following paragraph in the “Outcomes” section should be changed as follows: Outcomes Primary endpoint Time from randomisation until the first occurring of death or hospitalisation for heart disease (coronary heart disease, arrhythmia, atrial fibrillation, sudden death, resuscitated sudden death), stroke, transient ischaemic attack, peripheral arterial disease or heart failure or first onset of any condition listed above not present at baseline. Primary endpoints will be adjudicated by an independent endpoints committee blinded to treatment arm. Existing Text: Outcomes Primary endpoint Time from randomisation until the first occurring death, first onset, or hospitalisation for heart disease (coronary heart disease, arrhythmia, new onset/first recorded atrial fibrillation, sudden death, failed sudden death), stroke, or heart failure. Primary endpoints will be adjudicated by an independent Endpoint Committee blinded to the treatment arm.